Aclaris Therapeutics Inc. (ACRS) had a good day on the market for Monday December 09 as shares jumped 7.83% to close at $1.79. About 652,269 shares traded hands on 3,025 trades for the day, compared with an average daily volume of n/a shares out of a total float of 41.39 million. After opening the trading day at $1.66, shares of Aclaris Therapeutics Inc. stayed within a range of $1.88 to $1.66.
With today’s gains, Aclaris Therapeutics Inc. now has a market cap of $74.09 million. Shares of Aclaris Therapeutics Inc. have been trading within a range of $8.49 and $0.74 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively.
Aclaris Therapeutics Inc. is based out of Wayne, PA and has some 169 employees. Its CEO is Neal Walker.
Aclaris Therapeutics Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
